Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Hallett David 2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2026 3. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX] (Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CSO 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SALT LAKE CITY, UT 84101 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Class A Common Stock 287,928 D Class A Common Stock 277,759(1) D Class A Common Stock 28,454(2) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(3)	02/02/2035	Class A Common Stock	70,037	$7.25	D
Stock Option (Right to Buy)	(4)	12/18/2034	Class A Common Stock	740,686	$6.09	D
Stock Option (Right to Buy)	(5)	03/31/2032	Class A Common Stock	56,531	$0.01	D
Stock Option (Right to Buy)	(6)	03/31/2032	Class A Common Stock	75,375	$0.01	D
Stock Option (Right to Buy)	04/04/2026(7)	04/02/2033	Class A Common Stock	80,510	$0.01	D
Stock Option (Right to Buy)	(8)	04/02/2033	Class A Common Stock	80,510	$0.01	D
Stock Option (Right to Buy)	03/15/2025(9)	04/14/2034	Class A Common Stock	9,241	$0.01	D
Stock Option (Right to Buy)	04/17/2027(7)	04/14/2034	Class A Common Stock	150,888	$0.01	D
Stock Option (Right to Buy)	(10)	04/14/2034	Class A Common Stock	150,888	$0.01	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Hallett David C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY, UT 84101			CSO

Signatures

/s/Jonathan Golightly, attorney-in-fact		01/09/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents RSUs with each RSU representing the right to receive one share of Class A common stock. The RSUs vest in equal quarterly installments beginning February 15, 2025 through November 15, 2028, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
(2)	Represents RSUs with each RSU representing the right to receive one share of Class A common stock. The RSUs vest in equal quarterly installments beginning May 15, 2025 through February 15, 2029, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
(3)	The option vests as to one forty-eighth (1/48th) of the original 70,037 shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
(4)	The option vests as to one forty-eighth (1/48th) of the original 740,686 shares subject to the option on January 2, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
(5)	The option was vested as to 35,333 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 21,198 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2026, subject to Reporting Person continuing as a service provider though each vesting date.
(6)	This option is vested and fully exercisable.
(7)	This option will become vested and exercisable on the Date Exercisable subject to the Reporting Person continuing as a service provider through such date.
(8)	The option was vested as to 30190 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 50,320 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2027, subject to Reporting Person continuing as a service provider though each vesting date.
(9)	This option is vested and fully exercisable
(10)	The option was vested as to 18,862 shares upon the Issuer's assumption of the option at the time of the acquisition of Exscientia plc on November 20, 2024, and the remaining 132,026 shares vest in equal amounts quarterly, starting on December 15, 2024 through March 15, 2028, subject to Reporting Person continuing as a service provider though each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.